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INTRODUCTION
Tumor cells must manage their energetic resources to grow and survive. This involves coordinating metabolic activities to produce ATP, and the acquisition or synthesis of macromolecules (i.e., proteins, lipids, and nucleotides) at sufficient rates to meet the demands of malignant growth (Lunt and Vander Heiden, 2011) . A common characteristic of cancer cells is the reprogramming of cellular metabolism to favor metabolic pathways that fuel aberrant cell growth such as aerobic glycolysis (i.e., the Warburg effect) and mitochondrial metabolism (Vander Heiden et al., 2009; Weinberg and Chandel, 2015) . Many of the predominant oncogenic mutations observed in cancer also control tumor cell metabolism as part of their mode of action Jones and Thompson, 2009) , linking metabolic dysregulation to tumor progression.
One of the major drivers of metabolic reprogramming in tumor cells is the c-Myc proto-oncogene (hereafter referred to as Myc), a transcription factor overexpressed or deregulated in over 50% of human cancers including hematopoietic, brain, breast, colorectal, and lung malignancies (Bredel et al., 2009; Cancer Genome Research Atlas, 2012 Li et al., 2013; Schmitz et al., 2012) . Increased MYC expression is associated with poor prognosis in Burkitt Lymphoma (BL) (Lin et al., 2012b) and diffuse large B cell lymphoma (DLBCL) (Barrans et al., 2010; Savage et al., 2009; Zhou et al., 2014) , with an overall 5-year survival rate of only 30% (Savage et al., 2009 ).
Myc promotes the re-wiring of tumor cell metabolism through the transcriptional regulation of metabolic pathway genes, including enzymes that regulate glycolysis, tricarboxylic acid (TCA) cycle metabolism, oxidative phosphorylation (OXPHOS), and mitochondrial biogenesis (Stine et al., 2015) . Oncogenic Myc can also function as an amplifier of cellular gene expression programs (Lin et al., 2012a; Nie et al., 2012) , which may occur through non-specific ''invading'' of enhancer and promoter regions, or recruitment of specific cofactors, such as Miz1 and Max, that help shape transcriptional responses triggered by supraphysiological levels of oncogenic Myc (Wolf et al., 2015) . Myc also regulates the transcription of microRNAs (miRNAs), which are small, non-coding RNAs that negatively regulate mRNA stability and/or translation through partial complementary base pairing to the 3 0 UTR of target mRNAs (Bartel, 2009 ). Myc has been associated with widespread repression of miRNA expression (Chang et al., 2008) , but is also found to induce expression of the polycistronic miRNA cluster miR-1792. Originally identified as a candidate gene in the 13q31-q32 amplification observed in lymphoma (Ota et al., 2004) , miR-1792 is a direct transcriptional target of Myc (O'Donnell et al., 2005) and cooperates with Myc to promote lymphomagenesis in animal models (He et al., 2005) . miR-1792 expression is elevated in a number of human tumors, including cancers of the colon (He et al., 2005) , lung (Hayashita et al., 2005) , and DLBCL (Cerami et al., 2012; Olive et al., 2010; Pei et al., 2013) .
Recent work indicated that elevated miR-1792 expression can maintain tumor growth even when Myc is inactivated in tumors (Li et al., 2014) , suggesting that miR-1792 may mediate several of the pro-tumorigenic effects ascribed to Myc. Here, we describe an essential function for the Myc-regulated miRNA cluster miR-1792 in mediating Myc-driven metabolic reprogramming, implicating control of tumor metabolism as a central part of miR-1792 oncogenic activity.
RESULTS

miR-17-92 Regulates Glycolytic and Oxidative Metabolism in Lymphoma Cells
Myc has been characterized as a master regulator of tumor metabolism through the direct transcriptional regulation of metabolic enzymes involved in intermediary metabolism (Stine et al., 2015) . However, Myc also induces the expression of miR-1792, a polycistronic miRNA cluster which encodes six individ- ual miRNAs from a single RNA precursor ( Figure 1A ) (Olive et al., 2013) . To investigate the influence of miR-1792 on the metabolism of Myc + tumor cells, we used established Em-Myc B cell lymphomas harboring conditional floxed alleles of miR-1792 (miR-1792 fl/fl , denoted hereafter as fl/fl) (Mu et al., 2009 ). Examination of miRNA expression revealed miR-17, miR-20, and miR-92a as the most abundant mature miRNAs of the cluster expressed in Em-Myc lymphoma cells ( Figure 1B ). Parental fl/fl Em-Myc lymphoma cells were cultured with 4-OHT to generate isogenic tumor cells with homozygous deletion of miR-1792 (miR-1792 D/D , denoted as D/D) (Figures S1A and S1B). We did not observe compensation of mature miRNA expression from the paralogous clusters miR-106a363 or miR-106b25 in lymphoma cells lacking miR-1792 ( Figure S1C ). Deletion of miR-1792 led to a slight reduction in Em-Myc lymphoma cell proliferation as previously described (Mu et al., 2009 ) but did not significantly alter tumor cell viability (Figures S1D and S1E).
We next assessed the impact of miR-17-92 deletion on the metabolism of Myc + lymphomas by measuring their extracellular acidification rate (ECAR), a measure of aerobic glycolysis, and oxygen consumption rate (OCR), a measure of OXPHOS (Wu et al., 2007) . D/D lymphomas displayed an 50% reduction in both their ECAR and OCR compared to parental fl/fl lymphoma cells ( Figure 1C ). Consistent with the reduction in aerobic glycolysis, D/D lymphomas displayed lower glucose uptake and lactate production compared to lymphomas expressing miR-1792 ( Figure 1D ). Glutamine consumption and ammonia production (a measure of glutaminolysis) were similarly reduced in D/D lymphoma cells ( Figure 1E ). The expression of key metabolic enzymes involved in glycolysis (Hk2, Aldolase, Ldha) and glutaminolysis (Gls1, Gls2) were reduced in D/D lymphoma cells compared to fl/fl controls ( Figure S1F ). Proliferating D/D lymphoma cells also displayed reduced cell size relative to parental tumor cells ( Figure S1G ).
miR-1792 cooperates with Myc to promote lymphomagenesis and tumor progression in animal models (He et al., 2005) . To assess whether overexpression of miR-1792 was sufficient to alter the metabolic activity of lymphoma cells, we ectopically expressed miR-1792 in Raji cells ( Figure S1H ), a human BL cell line harboring a t(8;14)(q24;q32) MYC-IGH translocation (Hamlyn and Rabbitts, 1983) . Ectopic expression of miR-1792 increased the proliferative capacity but not the viability of Raji cells in culture (Figures S1I and S1J). In contrast to miR-1792 deletion, ectopic expression of miR-1792 increased both the ECAR and OCR of Raji cells ( Figure 1F ). We observed similar increases in both glucose consumption and lactate production ( Figure 1G ) and glutaminolysis ( Figure 1H ) in Raji cells overexpressing miR-1792. Together these data indicate that miR-1792 is both sufficient to drive enhanced metabolism and required for global maintenance of glycolytic and oxidative metabolism in Myc-dependent lymphoma cells.
miR-1792 Is a Global Regulator of Myc-Dependent Metabolic Reprogramming
We next set out to identify pathways under miR-1792 control by conducting RNA sequencing (RNA-seq) analysis of isogenic lymphoma cells expressing (fl/fl) or lacking (D/D) miR-1792. Deletion of miR-1792 promoted widespread changes in gene expression in Myc + lymphoma, with the expression of >5,700 genes significantly altered in D/D lymphomas relative to control cells ( Figure S2A ; Table S1 ). Analysis of KEGG pathways significantly decreased in D/D lymphomas revealed enrichment in metabolic pathway genes, mRNA transport and translation, and proteasome and peroxisome pathway components (Figure 2A) . Further analysis of the metabolic pathways genes influenced by miR-1792 revealed a global decrease in metabolic pathways including glycolysis, the TCA cycle ( Figure S2B ), components of the electron transport chain ( Figure S2C ), amino acid metabolism, the pentose phosphate pathway, serine biosynthesis, and nucleotide biosynthesis ( Figure 2A ). We next assessed overlap between the miR-1792-regulated transcriptome and known Myc target genes (Kim et al., 2010) . This analysis revealed that 45% of defined Myc target genes were significantly influenced by loss of miR-1792 ( Figure 2B ). Enriched in this group of miR-1792-dependent Myc-target genes were metabolic pathway genes involved in central carbon metabolism and cellular biosynthesis (i.e., amino acid, purine, and pyrimidine biosynthesis). Details of differentially expressed miR-1792-dependent Myc-target genes are summarized in Figure S2D and Table S2 .
We next assessed the impact of miR-1792 loss on metabolic network connectivity in Myc-dependent lymphoma cells. This analysis, which is based on connectivity between metabolite abundance and metabolic enzyme gene expression (Jha et al., 2015; Vincent et al., 2015b) , revealed several metabolic sub-networks dependent on miR-1792 expression ( Figure 2C ). This network-based analysis confirmed a global downregulation of cellular metabolic pathways at the transcriptional level in D/D lymphomas. Pathways decreased in miR-1792-deficient Em-Myc lymphoma cells included glycolysis, and key branching pathways from the glycolytic pathway supporting nucleotide biosynthesis (i.e., pentose phosphate and serine biosynthesis pathways). The network also revealed lower TCA cycle metabolism and glutathione biosynthesis in miR-1792-deficient lymphomas, while highlighting increases in genes associated with inositol biosynthesis and acetate metabolism (Acss1 and Aldh3b1). Taken together, these data suggest an active role for miR-1792 in enforcing the Myc-dependent metabolic transcriptome.
Myc-Dependent Regulation of Central Carbon Metabolism Requires miR-1792
Given the decreased glycolytic and oxidative metabolism of Myc + lymphoma cells lacking miR-1792 ( Figure 1 ), we conducted stable isotope tracer analysis (SITA) on fl/fl and D/D Em-Myc lymphoma cells by culturing them with either U-[ 13 C]glucose or -glutamine. D/D lymphoma cells displayed deceased overall abundance of intracellular metabolites involved in central carbon metabolism ( Figure 3A ). Total intracellular pyruvate and lactate levels were decreased by 50% in D/D Em-Myc cells ( Figure 3A) , due largely to reduced production of 13 C 3 -pyruvate and 13 C 3 -lactate isotopologues from glucose ( Figure 3B ). Similarly, the total abundance of TCA cycle metabolites including citrate and fumarate, as well as the incorporation of 13 Cglucose-derived carbon into these metabolite pools, were decreased in D/D cells relative to control lymphoma cells (Figures 3A and 3B) . The synthesis of glutamate from a-ketoglutarate, which is mediated by glutamate dehydrogenase (GLDH) in Myc-driven cancer cells (Bott et al., 2015) , was similarly decreased in Myc + lymphoma cells lacking miR-1792 (Figure 3A) . We observed a significant abundance of 13 C 3 isotopologues of citrate, fumarate, and glutamate (blue bar, m+3), suggesting contribution of pyruvate carboxylase (PC) activity to TCA cycle anaplerosis in Em-Myc lymphoma cells ( Figure 3B ). Decreased mRNA levels for the glucose transporters Glut1 (Slc2a1) and Glut3 (Slc2a3) were observed in D/D Em-Myc cells ( Figure S3 ), which may contribute to lower glucose utilization by these cells.
Myc is a major regulator of glutaminolysis (Gao et al., 2009; Wise et al., 2008) and regulates glutamine-dependent TCA cycle activity under basal and hypoxic conditions (Le et al., 2012) . However, we found that miR-1792 was required to support glutamine-dependent TCA cycle anaplerosis in Em-Myc lymphoma cells ( Figure 3C ). Incorporation of U-[ 13 C]-glutamine carbon into TCA intermediates was significantly reduced in D/D Em-Myc lymphoma cells, both in terms of total abundance ( Figure 3C ) and isotopomer distribution ( Figure 3D ). Of note, glutamine-dependent production of 13 C-citrate and 13 C-aspartate, which play essential roles in supporting cancer cell proliferation (Birsoy et al., 2015; Hatzivassiliou et al., 2005; Sullivan et al., 2015) , were significantly reduced in D/D Em-Myc lymphoma cells. 
(legend continued on next page)
miR-17 and -20 Drive Metabolic Reprogramming Downstream of Myc Given that the miR-1792 gene encodes six mature miRNAs comprising four seed families ( Figure 1A ), we next sought to determine which miRNAs contribute to the metabolic regulatory activity of the cluster. We engineered a series of miR-1792-deficient Em-Myc lymphoma cell lines re-expressing the full miRNA cluster (+1792) or mutant miR-1792 alleles lacking specific seed family members ( Figure 4A ). The relative expression of each mature miRNA in control (fl/fl) and miR-1792 mutant cell lines was verified by qPCR ( Figure S4A ). Seahorse analysis of these lymphoma cell lines revealed differential contributions of each miR-1792 seed family to the bioenergetic profiles of Em-Myc lymphoma cells ( Figure 4B ). Addback of the full miR-1792 cluster rescued the OCR and enhanced the ECAR of D/D cells, confirming our earlier results that elevated miR-1792 expression can enhance glycolysis ( Figures 1F and 1G ). Addback of the cluster lacking only miR-92a (D92) or miR-19a and miR-19b (D19a,b) increased both OCR and ECAR above levels seen in fl/fl cells, whereas addback of a mutant miR-1792 allele lacking the miR-17 family members miR-17 and miR-20a (D17,20) failed to rescue the ECAR and OCR of D/D cells ( Figure 4B ).
Further metabolic profiling was conducted using individual D/D lymphoma cell clones expressing all components of (C) Integrated metabolic network analysis for fl/fl versus D/D Em-Myc lymphoma cells. The direction and magnitude of fold changes in enzyme expression or metabolite abundance between conditions is indicated on a green (enriched in fl/fl) to red (enriched in D/D) color scale. Enzymes are represented by connecting lines between metabolites, with the color of the edge indicating the fold change and the thickness reflecting the significance of differential expression. Round nodes represent metabolites, with the differential abundance of each metabolite indicated by the size of the node. (legend continued on next page) miR-1792 except miR-17 and miR-20a (D17,20) . Lymphoma cells lacking miR-17/20 displayed similar reductions in glucose consumption ( Figure 4C ), lactate production ( Figure 4D ), glutamine consumption ( Figure S4B ), and ammonia production ( Figure S4C ) compared to D/D lymphoma cells, which was fully rescued only through addback of the full miR-1792 cluster. The reduction in glycolysis and glutaminolysis correlated with reduced levels of key glycolysis (Hk2, Aldolase, Ldha) and glutaminolysis (Gls2) enzymes in D17,20 lymphoma cells relative to control cells (either fl/fl or full miR-1792 addback) ( Figure 4E ). We next used SITA to assess whether the miR-17 seed family influences nutrient utilization by Myc + lymphoma cells. Control (fl/fl), miR-1792-deficient (D/D), miR-1792 addback, or D17,20 lymphoma cells were cultured in medium containing either U-[ 13 C]-glucose or -glutamine, and metabolite abundances determined by gas chromatography-mass spectrometry (GC-MS). Re-expression of miR-1792 was sufficient to restore both glucose-and glutamine-dependent metabolic flux in D/D lymphoma cells ( Figures 4F, 4G , and S4D-S4G). Ectopic miR-1792 expression actually enhanced metabolic flux in D/D lymphoma cells beyond control levels, marked by increased production of lactate from 13 C-glucose ( Figure 4F ) and TCA cycle metabolites from 13 C-glutamine ( Figures 4G and S4G) . In contrast, D17,20 lymphoma cells displayed similar 13 C-labeling patterns to D/D lymphoma cells ( Figures 4F and 4G) .
Finally, we assessed the contribution of miR-17/20 to the tumorigenic potential of Em-Myc lymphomas. While re-expression of full-length miR-1792 restored the proliferative capacity of D/D lymphoma cells to control levels, D17,20 failed to rescue lymphoma cell proliferation in vitro ( Figure 4H ). Next, we injected nude mice with control (fl/fl) or miR-1792-deficient Em-Myc lymphoma cells expressing full-length miR-1792 or D17,20, and monitored palpable tumor formation over time. While control lymphomas and D/D lymphomas re-expressing miR-1792 formed tumors rapidly (median onset of 2 weeks), the development of tumors lacking miR-17 and -20 (D17,20) was significantly slower, with an average latency of 4 weeks ( Figure 4I ). For one clone in particular (D17,20-2), >30% of animals remained tumor-free for up to 8 weeks, compared to 50% for animals who had received D/D lymphoma cells ( Figure 4I ).
LKB1 Is a Direct Target of the miR-17 Seed Family miRNAs act to repress mRNA translation or promote mRNA degradation via partial complementary binding to the 3 0 UTR of target mRNAs . Previous work has linked deregulated miR-19 expression to the lipid phosphatase Pten (Mu et al., 2009; Olive et al., 2009) , which may affect glycolysis through modulation of PI3K-Akt signaling. However, Pten protein levels were unaffected by loss of miR-1792 in D/D lymphoma cells ( Figure S5A ), and lymphoma cells lacking miR-19 did not display major changes in ECAR or OCR ( Figure 4B) .
We used the miRNA prediction algorithm Targetscan (Agarwal et al., 2015) and curated miRNA-mRNA interactions (Helwak et al., 2013) to identify Stk11, which encodes the serine-threonine kinase Liver Kinase B1 (LKB1), as a putative miR-17 family target. Previous work had identified LKB1 as a potential target of miR-17 in ovarian cancer cells (Liu et al., 2015) . The seed region of miR-17/20 was predicted to bind to one site (base pairs 122-130) in the mouse Stk11 3 0 UTR sequence ( Figure 5A ), and that this 3 0 UTR target site was retained across several mammalian species including humans ( Figure S5B ). This was intriguing given that haploinsufficiency of LKB1, rather than biallelic inactivation of the gene, is commonly associated with tumor development (Vaahtomeri and Mä kelä , 2011) . LKB1 is also a negative regular of tumor metabolism whose loss promotes the Warburg effect in tumors (Faubert et al., 2014; ). We conducted 3 0 -rapid amplification of cDNA end (RACE) using mRNA isolated from Em-Myc lymphoma cells and, consistent with previous reports (Smith et al., 1999) , found that Stk11 possesses an alternative poly-adenylation sequence that gives rise to both short and long 3 0 UTR isoforms (denoted S1 and L1, for short and long, respectively) that contain the miR-17/20 targeting sequence ( Figure S5C ).
We next assessed whether miR-17 directly acts on the 3 0 UTR of Stk11 mRNA to regulate its expression. We first used a reporter assay in which the Stk11 3 0 UTR was cloned downstream of a luciferase reporter gene to assess miRNAdependent suppression of the 3 0 UTR sequence. Normalized luciferase activity was reduced in 293T cells expressing either the S1 or L1 form of the Stk11 3 0 UTR ( Figure S5D ), indicating suppression of this 3 0 UTR by endogenous miRNAs or other RNA binding proteins. The Stk11 3 0 UTRs were suppressed further by ectopic expression of miR-17 ( Figure 5B ). Mutating the complementary miR-17 target site ( Figure 5A ) abolished miR-17-dependent regulation of the Stk11 3 0 UTR in this assay ( Figures 5B and S5D) .
We next expressed FLAG-tagged versions of LKB1 in 293T cells using expression constructs encoding Stk11 mRNA with no 3 0 UTR (D), wild-type 3 0 UTR (WT), or a mutated 3 0 UTR lacking complementarity with the miR-17 seed region (MUT) (Figure S5E) . Protein levels of FLAG-LKB1 were reduced in cells expressing the wild-type Stk11 3 0 UTR when co-transfected with a miR-17 expression vector ( Figure 5C ). Conversely, FLAG-LKB1 with the mutant Stk11 3 0 UTR was refractory to miR-17 expression ( Figure 5C ). We next examined the impact of miR-17/20 on LKB1 expression in lymphoma cells. LKB1 protein levels were elevated in D/D Em-Myc lymphoma cells compared to control cells ( Figure 5D ). Stk11 mRNA levels were unaffected by deletion of miR-1792 ( Figure 5E ), suggesting a mechanism of translational suppression of LKB1 mRNA by miR-17. In contrast, LKB1 protein levels were reduced in Raji cells ectopically expressing miR-1792 ( Figure 5F ). Lymphoma cells lacking miR-17 and -20 expression (D17,20) displayed elevated LKB1 expression similar to miR-1792-deficient lymphomas, whereas addback of the entire miR-1792 cluster potently reduced LKB1 protein levels in Em-Myc lymphoma cells ( Figure 5G ).
miR-1792
Regulates mTORC1 Signaling in Lymphoma through LKB1 Silencing LKB1 is a tumor suppressor mutated in a number of human cancers and plays a central regulatory role in tumor metabolic and cell growth control through downstream effects on AMPK and mTOR signaling . One prediction of our findings was that miR-1792 may influence these pathways through suppression of LKB1-dependent signaling. Deletion of miR-1792 promoted an increase in basal AMPK signaling, as determined by increased AMPKa phosphorylation at Thr-172 and increased phosphorylation of the AMPK targets ULK1 (Ser-555) and Raptor (Ser-792) in D/D lymphoma cells ( Figure 6A ). mTORC1 pathway activity, as determined by rS6 (B) 293T cells expressing FLAG-Ago2 (293T-Ago2) were transfected with empty vector (EV) or luciferase reporter constructs for the short (S1) or long (L1) variants of the mouse Stk11 3 0 UTR containing either the wild-type (WT) or mutated (MUT) miR-17 family recognition site as in (A). Cells were co-transfected with (+) or without (-) a miR-17x4 expression plasmid. Shown is the mean ± SEM for the FLuc/RLuc ratio for triplicate samples, normalized to control cells (EV). (C) Immunoblot of FLAG-LKB1 protein expression in 293T-Ago2 cells co-transfected with (+) or without (-) a miR-17x4 expression plasmid and FLAG-LKB1 expression plasmids lacking the 3 0 UTR (D), or containing the WT or MUT 3 0 UTR sequence fused to the Stk11 CDS. Shown are protein levels for FLAG-LKB1 and FLAG-Ago2 for the S1 (top) and L1 (bottom) Stk11 3 0 UTR isoforms. and 4EBP phosphorylation, was decreased in D/D lymphoma cells ( Figure 6B ). Similar patterns of increased AMPK activity and decreased mTORC1 activity were observed in lymphoma cells specifically lacking miR-17 and -20 (D17/20, Figure 6C ), implicating the miR-17 seed family as a mediator of these signaling changes. Reducing LKB1 levels in D/D lymphoma cells by stable short hairpin RNA (shRNA) expression ( Figure 6D ) reversed the effects of miR-1792 deletion on AMPK and mTORC1 pathway activity ( Figure 6E ).
LKB1 Suppression by miR-17 Dictates Metabolic
Reprogramming and Tumorigenic Potential of Myc + Lymphomas We next examined the contribution of miR-17/20-dependent suppression of LKB1 to the metabolic reprogramming that drives Myc + lymphoma growth. Silencing LKB1 increased metabolic enzyme expression in D/D lymphoma cells compared to D/D cells transduced with a control shRNA hairpin ( Figure 7A) . The recovery of metabolic gene expression in LKB1 shRNA-expressing D/D lymphoma cells correlated with increased ECAR and OCR levels ( Figure 7B ), increased glucose consumption and lactate production ( Figure S6A ), and increased glutaminolysis (Figure S6B ) in these cells. We next cultured D/D lymphoma cells expressing control or LKB1 shRNAs with either U-[ 13 C]-glucose ( Figures 7C and S6C ) or U-[ 13 C]-glutamine ( Figures 7D and  S6D ). Silencing LKB1 in D/D lymphomas restored the defects in central carbon metabolism normally seen in these cells and was characterized by a re-emergence of Warburg metabolism ( 13 C-glucose to lactate conversion, Figure 7C ) and increased contribution of both glucose and glutamine to the TCA cycle ( Figures 7C, 7D, S6C, and S6D ). Finally, we examined whether silencing LKB1 was sufficient to rescue the tumorigenic potential of lymphoma cells lacking miR-1792. Expression of shRNAs targeting LKB1 reversed the proliferative defect of D/D lymphoma cells in vitro ( Figure 7E ). When injected into nude mice, D/D lymphoma cells expressing LKB1 shRNA (D/D+shLKB1) formed palpable lymph node tumors with latency similar to wild-type Em-Myc lymphomas expressing miR-1792 (fl/fl) ( Figure 7F ), despite the fact that these cells lacked expression of any mature miR-1792-derived miRNAs. These data indicate that the effects of miR-1792 loss on cell metabolism and tumor growth can be overcome simply by disrupting LKB1 signaling, highlighting the miR-17-LKB1 circuit as a key regulator of tumor metabolism and growth.
DISCUSSION
Myc is among the most implicated genes in human cancer (Zack et al., 2013) and has been shown to coordinate multiple cellular behaviors in support of malignancy (Dang, 2012) . Here, we describe a new paradigm for Myc-dependent metabolic reprogramming involving the polycistronic miRNA miR-1792. Using isogenic Myc-dependent lymphoma cells lacking miR-1792, we demonstrate that miR-1792 is a critical regulator of metabolic reprogramming in Myc + tumors. We show that miR-1792 is required to sustain both glycolytic and oxidative metabolism and promote multiple anabolic pathways required for tumor growth, while amplified miR-1792 expression, which is observed in many tumor types, is sufficient for cell autonomous upregulation of tumor metabolic activity. Our data implicate the miR-17 seed family (comprising miR-17 and miR-20) as the key regulatory element of miR-1792 that influences both metabolic reprogramming and the oncogenic potential of Myc-dependent lymphomas through negative regulation of the LKB1 tumor suppressor. Our results establish metabolic reprogramming as a central function for miR-1792 and implicate metabolic control as an essential part of the oncogenic activity of this miRNA cluster.
Previous work has established miR-1792 as an oncogenic miRNA cluster through its ability to promote tumor cell proliferation, cell viability, and angiogenesis while inhibiting cellular differentiation and senescence (Dews et al., 2006; Olive et al., 2010 Olive et al., , 2013 . Our data extend the regulatory repertoire of miR-1792 to include many of the core metabolic processes in cancer. Although Myc can influence specific metabolic nodes such as glutaminolysis through suppression of miRNAs targeting metabolic enzymes (Gao et al., 2009) , our data indicate that miR-1792 functions broadly to support Myc-dependent metabolic programs. Loss of miR-1792 in Em-Myc lymphoma cells leads to reduced transcription of core bioenergetic pathway genes (glycolysis; TCA cycle; OXPHOS) while simultaneously altering anabolic pathways (pentose phosphate pathway; biosynthesis of serine, aspartate, and glutamine; purine and pyrimidine metabolism) and ribosome biogenesis. This global reduction in metabolic pathway gene expression is coupled to reduced nutrient consumption and processing, including glucose and glutamine, which serve as two major carbon sources for lymphoma growth.
Although miR-1792 cooperates with Myc to promote tumor aggressiveness (He et al., 2005; Mu et al., 2009; Olive et al., 2009) , recent work has demonstrated Myc-independent roles for miR-1792 in tumor maintenance (Li et al., 2014) . Our data indicate that miR-1792 expression influences almost 50% of the Myc-regulated transcriptome in Myc + lymphomas. Included in this regulation are a majority of metabolic pathway genes previously established as Myc targets (Lin et al., 2012a; Wang et al., 2011) , suggesting that many of the effects on metabolic reprogramming ascribed to Myc route through miR-1792. These observations counter the argument that the reduced metabolism of miR-1792-deficient (D/D) and miR-17/20-deficient (D17,20) lymphoma cells is simply a by-product of reduced cell size and/or proliferation but rather reflects the action of the cluster on global metabolic gene expression. Given the broad effect of miR-1792 loss on metabolic gene expression, it is unlikely that miR-1792 directly regulates these genes through direct miRNA:mRNA pairing. We speculate that miR-1792 functions to reinforce Myc-dependent metabolic reprogramming indirectly by broadly regulating the expression of transcription factors (or other regulators) involved in metabolic reprogramming.
Processing of primary miR-1792 (pri-miR-1792) transcripts results in differential expression of mature miRNA species in tissues (Du et al., 2015), with miR-17, -20, and -92 being the most abundant mature miRNAs produced from the miR-1792 cluster in the lymphoma cells tested. Evidence shows that miR-17 is often the most expressed miRNA of the cluster in tumors (Knudsen et al., 2015; Yu et al., 2010) . Lymphoma cells lacking miR-17 and -20 (D17,20) display increased LKB1 expression, decreased mTORC1 activity, and deficiencies in glycolytic and oxidative metabolism identical to tumor cells lacking miR-1792. Beyond its role in cancer, miR-1792 plays important roles in other biological processes including hematopoietic cell development, stem cell renewal, and axial patterning (Olive et al., 2013) . Based on our data, we hypothesize that metabolic regulation is a central function of miR-17 family miRNAs under both normal and pathological conditions.
Our finding that LKB1 is repressed by miR-17 family miRNAs establishes a regulatory link between oncogenic Myc signaling and the LKB1 tumor suppressor pathway. LKB1 has wideranging impact on tumor growth and metabolism, in part by modulating AMPK and mTORC1 activity . Reduced LKB1 signaling promotes the development of tumors with high mTORC1 activity and an aggressive metabolic phenotype Faubert et al., 2014; Shaw et al., 2004) . Somatic inactivating mutations in LKB1 are observed in many cancers, including 30% of nonsmall cell lung cancer (NSCLC) cases (Gill et al., 2011) . However, biallelic loss of LKB1 is rare among tumors with inactivating LKB1 mutations. Rather, haploinsufficiency of LKB1, similar to other tumor suppressors including Tsc2, Pten, and Smad4, is sufficient to promote tumorigenesis (Yoo et al., 2002) , arguing that gene dosage is critical for LKB1-dependent tumor suppression. In this regard, miR-1792-dependent post-transcriptional regulation of LKB1 may help fine-tune its tumor suppressor functions. This has clear implications for the tumorigenic potential of Myc + tumors, as silencing LKB1 reverses the severe metabolic and growth defects of lymphoma cells lacking miR-1792.
Our results indicate that post-transcriptional regulation of LKB1 by miRNAs can allow tumor cells to bypass LKB1-mediated growth suppression without the need for inactivating STK11 mutations. This raises the possibility that miRNAdependent tuning of LKB1 levels may be a general mechanism for balancing cellular bioenergetics and cell growth in cancer, and may contribute to the pathophysiology of LKB1-regulated diseases such as Peutz-Jeghers syndrome. It is possible that endogenous miRNAs in addition to miR-17 are capable of silencing LKB1 in tumor cells and that miRNAs targeting other components of the LKB1 complex, such as miR-451 (Godlewski et al., 2010) , may exert similar effects on tumor metabolism by influencing LKB1-dependent signaling. miR-17 and -20 belong to a larger miRNA family that includes miR-93, -106a, and -106b, all sharing a common seed sequence (5 0 -AAA GUG-3 0 ). Interestingly, miR-106a and -106b, which are also encoded by miRNA clusters (miR-106a363 and miR-106b25, respectively), are also associated with oncogenesis (Conkrite et al., 2011; Landais et al., 2007) , although our data suggest that these miRNAs do not compensate for the loss of miR-1792 in the lymphoma cells examined here. Whether related miR-17 family members also influence LKB1 expression and/or tumor metabolism remains to be determined. Together our data highlight a central role for miR-1792 in balancing both metabolic advantage and growth potential in cancer.
EXPERIMENTAL PROCEDURES
Cell Lines, DNA Constructs, and Cell Culture The generation of Em-Myc Cre-ERT2 + ;miR-1792 fl/fl lymphoma cells has been described previously (Mu et al., 2009) . Em-Myc cells were cultured on a layer of irradiated Ink4a-null MEF feeder cells in DMEM and IMDM medium (50:50 mix) supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and b-mercaptoethanol. Raji cells were cultured in RPMI medium supplemented with 10% FBS and 2 mM glutamine. Retroviral-mediated gene transfer into lymphoma cells was conducted as previously described .
For growth assays, cells were seeded at a density of 1 3 10 5 cells/ml in 3.5-cm dishes, and cell counts were determined via trypan blue exclusion using a TC20 Automated Cell Counter (Bio-Rad). For viability measurements, cells were stained with Fixable Viability Dye eFluor 780 (eBioscience) and analyzed using a Gallios flow cytometer (Beckman Coulter) and FlowJo software (Tree Star). Cell size was determined by forward scatter using flow cytometry.
Seahorse Analysis and Metabolic Assays
OCR and ECAR were determined using an XF96 Extracellular Flux Analyzer (Seahorse Bioscience) using established protocols (Faubert et al., 2014; Vincent et al., 2015a) . For media metabolite determination, cells were cultured for 2 days, and culture medium was analyzed for extracellular metabolites (glucose, glutamine, lactate, and ammonia) using a BioProfile Analyzer (NOVA Biomedical) as previously described (Vincent et al., 2015a) . Metabolic parameters were assessed in lymphoma cells undergoing logarithmic growth and standardized to cell number.
For metabolomics experiments using 13 C-labeled glucose or glutamine, lymphoma cells (3-5 3 10 6 per 3.5-cm dish) were cultured for 2 hr in glucose-and glutamine-free DMEM/IMDM (50:50 mix) containing 10% dialysed FBS (Wisent Bio Products) and either uniformly labeled [ 13 C]-glucose or [ 13 C]-glutamine (Cambridge Isotope Laboratories). 12 C-glutamine (2 mM) or -glucose (25 mM) were added back to the culture medium depending on the tracer used. Cells were washed twice with saline and then lysed in ice-cold 80% methanol, sonicated, derivatized as tert-butyldimethylsilyl (TBDMS) esters, and analyzed by GC-MS using previously described protocols Faubert et al., 2014; McGuirk et al., 2013) . Metabolite abundance was expressed relative to an internal standard (D-myristic acid) and normalized to cell number. Additional experimental details are described in Supplemental Experimental Procedures.
Immunoblotting, Quantitative Real-Time PCR, and RNA Sequencing Lymphoma cell lines were subjected to SDS-PAGE and immunoblotting using CHAPS and AMPK lysis buffers as previously described . Primary antibodies against hexokinase 2, aldolase, LDHA, GLS2, b-actin, 4EBP (total, phospho-T36/47, and phospho-S65), rS6 (total and phospho-S235/236), ULK (total and phosphor-S555), Raptor (total and phospho-S792), AMPKa (total and phospho-T172), and FLAG-tag were obtained from Cell Signaling Technology. Primary antibody against LKB1 (Ley 37D/G6) was from Santa Cruz Biotechnology.
For qPCR quantification of mature miRNAs, Qiazol was used isolate RNA, miRNEasy Mini kit was used to purify miRNAs and total mRNA, and cDNA synthesized using the miScript II RT kit (QIAGEN). qPCR was performed using the SensiFAST SYBR Hi-ROX kit (Bioline) and an AriaMX Real Time Pcr system (Agilent Technologies). miScript primer assays (QIAGEN) were used to detect mature miRNAs of the miR-1792 cluster, with miRNA expression normalized relative to U6 RNA levels. RNA preparation and library construction for RNA sequencing was conducted as previously described (Jha et al., 2015) . Libraries were sequenced using a HiSeq 2500 (Illumina) using 40 bp by 10 bp pair-end sequencing. Gene set enrichment analysis (GSEA) on RNAseq data was conducted using the gage function and non-parametric Kolmogorov-Smirnov test from the GAGE R Bioconductor package (Luo et al., 2009) . Network integration of RNA-seq and metabolite datasets was conducted as previously described (Jha et al., 2015) . Additional experimental details are described in Supplemental Experimental Procedures.
3 0 UTR Cloning and Validation 3 0 UTR isoforms for mouse Stk11 were determined by 3 0 RACE as previously described (Wu et al., 2010) . GeneArt DNA fragments (Life Technologies) for either the wild-type Stk11 3 0 UTR or harboring a mutated miR-17 seed region (bases 2-8 in the seed region) were cloned into the XhoI/XbaI sites of the pmirGLO vector (Promega). 293T cells (10 5 cells/well) stably expressing FLAG-Ago2 (Valdmanis et al., 2012) were transfected with individual pmirGLO-3 0 UTR constructs with or without co-transfection of a miR-17 expression plasmid (miR-17x4) (Hong et al., 2010) . Cells were lysed 48 hr post-transfection, and the ratio of luciferase to renilla luciferase activity determined using a Dual-Glo Luciferase assay kit (Promega) and a FLUOstar Omega plate reader. FLAG-tagged LKB1 expression constructs were generated by PCR amplification of the full-length LKB1 coding sequence from Em-Myc lymphoma RNA, using sequence specific primers to amplify inserts with short or long forms of the Stk11 3 0 UTR.
Tumor Xenograft Assays
Lymphoma cells were resuspended in Hank's balanced salt solution (HBSS) and injected intravenously (10 6 cells/mouse in 200 ml) into CD-1 nude mice (Charles River Laboratories). Tumor onset was monitored by palpation of inguinal and axillary lymph nodes, and tumor-free survival scored as the time elapsed between injection and first detection of palpable tumors as previously described . All procedures were carried out in accordance with guidelines of the Canadian Council on Animal Care, as approved by the Animal Care Committee of McGill University.
Statistical Analysis
Statistics were determined using paired Student's t test, ANOVA, or log-rank (Mantel-Cox) using Prism software (GraphPad) unless otherwise stated. Data are calculated as the mean ± SEM for biological triplicates and the mean ± SD for technical replicates unless otherwise stated. Statistical significance is represented in figures by *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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